Abstract: Techniques for monitoring cerebral blood metrics such as cerebral blood flow, cerebral blood volume and/or heart rate are provided. In some embodiments, techniques involve a headset with at least one laser configured to emit light into the brain and one or more light detectors such as CMOS sensors that generate information indicative of light reflected from one or more structures within the brain, which can be used to determine the cerebral blood metrics. Each light detector may be positioned within 5 mm of the scalp in some cases.

Abstract: Techniques for determining stroke risk are provided. In some embodiments, the techniques may involve causing, using one or more light sources disposed on a headset worn by a user, light to be emitted into the head of the user. The techniques may involve obtaining, using one or more light detectors disposed on the headset, information indicative of light reflected from one more structures within the head, wherein a portion of the obtained information spans a time period during which the user was holding their breath. The techniques may involve based on the obtained information, determining one or more cerebral blood metrics. The techniques may involve providing a representation of the one or more cerebral blood metrics as input to a trained machine learning model, and determining a likelihood the user will experience a stroke over a predetermined future time period based on an output of the trained machine learning model.

Abstract: Embodiments of the present invention provide a method for sharing an application between terminals, and a terminal, so as to facilitate user operations at a receiving end. The method includes: generating, by a first terminal according to an application that has been installed, a shared application installation package of the application; sending, by the first terminal, the shared application installation package to a second terminal, so that the second terminal installs the shared application installation package; determining, by the first terminal, shared data of the application that has been installed, where the shared data is data that is from an application server and required for the application to run; and sending, by the first terminal, the shared data to the second terminal, so that the second terminal uses the shared data when running the shared application.

Abstract: This application discloses a method for controlling an electronic device to perform photoplethysmography detection. The method includes obtaining historical detection data of a photoplethysmography sensor, calculating a confidence of the historical detection data, determining, based on the calculated confidence of the historical detection data, whether a light source to be turned on by the photoplethysmography sensor in a next detection time segment includes a light source different from a light source turned on when the historical detection data is obtained, and determining that a photoelectric sensing element to be turned on in the next detection time segment is a photoelectric sensing element corresponding to the determined light source to be turned on.

Abstract: A container device may have an outer shell that has an opening that is sealed by a closure mechanism. The closure mechanism may include resealable closure elements that are configured to partially or wholly seal the opening. In some examples, the closure elements may include magnetic strips that are formed with a first member, a second member, and a plurality of magnetic elements. In addition, the closure mechanism may include curved members to prevent the opening from closing when the closure mechanism is in an open configuration.

Abstract: Herein in provided a recombinant polypeptide comprising a polypeptide for preventing or reducing interaction between the human proteins EAG2 and KvB2, and a cell-penetrating peptide. The polypeptide may comprise a portion of Kvß2 from or encompassing a region that is important for the interaction between the two proteins, such as, e.g., a contiguous portion of human Kvß2 (SEQ ID NO: 26) encompassing at least amino acids 90 to 114 thereof. Retro-inverso polypeptides based on such recombinant polypeptides are also described. The EAG2-Kvß2 complex is herein identified as a therapeutic target for certain cancers. Herein are also disclosed therapeutic applications of the recombinant polypeptide in treatment of such cancers, including gliomas, such as low-grade gliomas or glioblastomas, which may be recurrent and/or resistant to conventional treatment.

Abstract: The present disclosure provides a method and apparatus for adjusting a virtual face model, an electronic device and a storage medium, so as at least to solve the technical problems of tedious operation steps and poor user experience of conventional solutions for adjusting a virtual image. A specific implementation solution includes: a real human face in a reality scene is identified to obtain a first virtual face model of the real human face in a virtual scene; in response to a face-pinching operation acting on the real human face, the face-pinching operation is identified to determine at least one to-be-adjusted key point in the first virtual face model and an adjustment manner of the at least one to-be-adjusted key point; and the first virtual face model is adjusted to a second virtual face model based on the adjustment manner of the at least one to-be-adjusted key point.

Abstract: Embodiments of the present invention provide a method for sharing an application between terminals, and a terminal, so as to facilitate user operations at a receiving end. The method includes: generating, by a first terminal according to an application that has been installed, a shared application installation package of the application; sending, by the first terminal, the shared application installation package to a second terminal, so that the second terminal installs the shared application installation package; determining, by the first terminal, shared data of the application that has been installed, where the shared data is data that is from an application server and required for the application to run; and sending, by the first terminal, the shared data to the second terminal, so that the second terminal uses the shared data when running the shared application.

Abstract: A prone cushion having at least one layer of material, a neck portion, and a torso portion being designed to support a user who is reclining in a prone position. The prone cushion may be adapted to have an upper layer and a bottom layer. The prone cushion my have a leg cavity for storing a height adjustment leg. The height adjustment leg may be stowed in the leg cavity when not in use, or may be placed under the prone cushion to adjust the height while in use. The density of the cushion may vary along the length of the cushion by inserting a plurality of holes into the at least one layer of material.

Abstract: Various embodiments are described for tracking and enabling access to information about key access patterns for database tables managed by a database service of a service provider network. Storage nodes can store data as key-value pairs (or key-document pairs), where the records or documents of a database are addressed by a unique key for each record. The storage nodes over time receive requests to perform various operations (for example, to get, put, update, or delete data in a table) associated with records stored by the storage nodes. Key access information extractors collect information regarding the keys accessed and send the information to a key tracking service. Key tracker nodes of the service can collect the data and send it to aggregator nodes. The aggregator nodes can determine a frequency with which such requests are received for keys of a partition or table to which the aggregator node is assigned.

Abstract: The present disclosure is drawn to bio-ink printer components, methods of printing bio-inks, and multi-fluid live cell printing systems. In one example, a bio-ink printer component can include a bio-ink and a bio-ink ejector fluidly connected or connectable to the bio-ink. The bio-ink can include a buffer solution that is suitable for live cells, and a polymer that includes polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl sulfate, polyethylene glycol, polyester, poly(dimethylsiloxane), cellulose, polysaccharide, or a combination thereof. The bio-ink ejector can include an ejection nozzle and a thermal resistor positioned to heat the bio-ink to form a vapor bubble to eject a droplet of bio-ink from the ejection nozzle.

Abstract: Embodiments of the present invention provide a method for sharing an application between terminals. The method includes: generating, by a first terminal according to an application that has been installed, a shared application installation package of the application; sending, by the first terminal, the shared application installation package to a second terminal; determining, by the first terminal, shared data of the application that has been installed, where the shared data is data that is from an application server and required for the application to run; and sending, by the first terminal, the shared data to the second terminal. In the embodiments of the present invention, when sharing an application, two terminals not only share an installation package of the application, but also share shared data of the application.

Abstract: The present invention relates to a sunscreen cosmetic for application to a user's skin. The sunscreen cosmetic is provided with a mineral including zinc oxide, titanium dioxide, or a combination of both. The sunscreen cosmetic also includes a high buffering-capacity agent configured to react with an external acidic source coming in contact with the cosmetic and to inhibit release of zinc ions from the zinc oxide and/or to inhibit release of titanium ions from the titanium dioxide.

Abstract: A method includes displaying a physiological parameter measurement interface comprising a plurality of physiological parameter identifiers, receiving a physiological parameter measurement operation, wherein the physiological parameter measurement operation comprises an operation of selecting, among the physiological parameter identifiers, a first physiological parameter identifier and a second physiological parameter identifier; and measuring, in response to the physiological parameter measurement operation, a first physiological parameter and a second physiological parameter of a measured object using a physiological parameter sensor of the electronic device.

Abstract: A method includes sending, by an application that is to obtain a verification code, a verification code obtaining request to a server, where the application that is to obtain a verification code is installed on a terminal, and where applications installed on the terminal further include an input method application and a short message service (SMS) message application; receiving, by the SMS message application, an SMS message that includes a verification code and that is sent by the server; and reading, by the input method application, the verification code in the SMS message, where the terminal does not allow an application other than the input method application and the SMS message application to read an SMS message in the terminal.

Abstract: Various embodiments relate to the field of communications technologies, and provide a light adjustment method and a terminal to resolve a problem that an existing light therapy device cannot flexibly adjust light based on a light requirement of a user and cannot more intelligently adjust a circadian rhythm of the user. In those embodiments, an awake time period and a sleep time period of a user is determined by the terminal, and parameter thresholds in the awake time period and the sleep time period is determined by the terminal. In those embodiments, a light parameter in a current time period is obtain by the terminal, and based on the light parameter in the current time period, a light parameter of light emitted by a light source device is then adjusted by the terminal.

Abstract: The core active components of the present composition, termed as de-ironizing inducers (DII), has a reducing agent and a precipitating agent. Molar ratios of the reducing agent with the precipitating agent range from 1:3-6 and the core components in the skincare product range from 0.1% to 10% w/w. The pH value of the skincare product is between 6.6 and 7.4. The skin care products can safely and effectively 5 remove iron in the skin, which has been shown to accelerate the visible signs of aging. The core components can also be used in combination with conventional skincare product compounds to achieve better anti-aging effects.

Abstract: A flood risk prediction method includes: collecting basic meteorological hydrological data of a basin by using a data collection and storage box; calibrating a basin hydrological model and a machine learning model; obtaining a meteorological simulation series under M groups of climate change scenarios and driving the basin hydrological model and the machine learning model to simulate a basin hydrological process under a future scenario; establishing a water and heat coupling balance equation of the basin to obtain annual average underlying surface feature parameters of the basin; extracting feature values of a flood duration and a flood volume and with the feature parameters as co-variates, establishing a joint probability distribution function; obtaining a joint return period of the flood duration and the flood volume; based on a dataset of the shared socioeconomic pathway, deriving a social economic exposure degree of future flood risk increase.

Abstract: The present disclosure belongs to the biopharmaceutical field, and discloses uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system, and particularly uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system with symptoms of cough and/or expectoration and/or asthma. As indicated by the test results of the present disclosure, Trezastilbenoside has significant efficacy of relieving cough, eliminating phlegm, relieving asthma and anti-inflammation, and has a potential therapeutic effect on respiratory system diseases, thus possessing broad prospects in clinical application.